Automated Imaging Differentiation of Parkinsonism

The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Parkinson Disease Autonomic Nervous System Diseases Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Cranial Nerve Diseases Eye Diseases Movement Disorders Multiple System Atrophy Multiple System Atrophy, Parkinson Variant Nervous System Diseases Neurodegenerative Diseases Neurologic Manifestations Ocular Motility Disorders Ophthalmoplegia Paralysis Parkinsonian Disorders Pathological Conditions, Signs and Symptoms Primary Dysautonomias Progressive Supranuclear Palsy Signs and Symptoms Supranuclear Palsy, Progressive Synucleinopathies Tauopathies

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ottawa Hospital Research Institute, Ottawa, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Parkinson's disease diagnosis within 5-9 years of baseline date
MSAp diagnosis
PSP diagnosis

Exclusion criteria

metal implants in the body that preclude an MRI (pacemaker, metallic clip, neurostimulator, etc)
claustrophobia
pregnancy

Treatment and study plan

AIDP

Diagnostic Test

Machine learning algorithm of imaging data

Primary outcomes

Predicted diagnosis accuracy

Time frame: 12-18 months

utilizing the automated imaging differentiation of Parkinsonism (AIDP) tool to predict diagnosis compared to the expertise of two movement disorder specialists

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Collaborators

Albany Medical College
Augusta University
Beth Israel Deaconess Medical Center
Centre for Addiction and Mental Health
Duke University
Johns Hopkins University
Massachusetts General Hospital
National Institute of Neurological Disorders and Stroke (NINDS)
Northwestern University
Ottawa Hospital Research Institute
Penn State University
University of Alabama at Birmingham
University of California, San Diego
University of California, San Francisco
University of Chicago
University of Kentucky
University of Michigan
University of Minnesota
University of South Florida
Wake Forest University
Washington University School of Medicine

Registry information

Acronym: AIDP

Important dates

Study start: 2021
Primary completion: 2027
Study completion: 2027
First posted: Jun 22, 2023
Registry last updated: Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed